BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nicholson JR, Sommer B. The research domain criteria framework in drug discovery for neuropsychiatric diseases: focus on negative valence. Brain Neurosci Adv 2018;2:2398212818804030. [PMID: 32166151 DOI: 10.1177/2398212818804030] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Smith NJ, Markowitz SY, Hoffman AN, Fanselow MS. Adaptation of Threat Responses Within the Negative Valence Framework. Front Syst Neurosci 2022;16:886771. [DOI: 10.3389/fnsys.2022.886771] [Reference Citation Analysis]
2 Kelly JR, Gillan CM, Prenderville J, Kelly C, Harkin A, Clarke G, O'Keane V. Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective. Front Psychiatry 2021;12:800072. [PMID: 34975593 DOI: 10.3389/fpsyt.2021.800072] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
3 Martens MAG, Filippini N, Harmer CJ, Godlewska BR. Resting state functional connectivity patterns as biomarkers of treatment response to escitalopram in patients with major depressive disorder. Psychopharmacology (Berl) 2021. [PMID: 34477887 DOI: 10.1007/s00213-021-05915-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Davidson M, Gabos-Grecu C. Do DSM classifications help or hinder
drug development?
. Dialogues Clin Neurosci 2020;22:73-9. [PMID: 32699507 DOI: 10.31887/DCNS.2020.22.1/mdavidson] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Strauss GP, Bartolomeo LA, Harvey PD. Avolition as the core negative symptom in schizophrenia: relevance to pharmacological treatment development. NPJ Schizophr 2021;7:16. [PMID: 33637748 DOI: 10.1038/s41537-021-00145-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
6 Wendt FR, Pathak GA, Tylee DS, Goswami A, Polimanti R. Heterogeneity and Polygenicity in Psychiatric Disorders: A Genome-Wide Perspective. Chronic Stress (Thousand Oaks) 2020;4:2470547020924844. [PMID: 32518889 DOI: 10.1177/2470547020924844] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
7 Mazarati A. Can we and should we use animal models to study neurobehavioral comorbidities of epilepsy? Epilepsy Behav 2019;101:106566. [PMID: 31699663 DOI: 10.1016/j.yebeh.2019.106566] [Reference Citation Analysis]
8 Sartori SB, Singewald N. Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders. Pharmacol Ther 2019;204:107402. [PMID: 31470029 DOI: 10.1016/j.pharmthera.2019.107402] [Cited by in Crossref: 44] [Cited by in F6Publishing: 50] [Article Influence: 14.7] [Reference Citation Analysis]